# DefEYE Raises Seed Round from ExSight Ventures to Accelerate Ocular Biologics Commercialization

> financing · REPORTED · 2025-11-01

DefEYE, Inc. raised an undisclosed seed funding round from ExSight Ventures in November 2025, with proceeds earmarked to accelerate commercialization and expansion of its decellularized placental tissue solutions for eye care and to launch new products in North America and Europe. The company reported nearly 70% year-over-year sales growth in 2024.

About DefEYE, Inc.: DefEYE, Inc. is an independent ophthalmic biologics company commercializing decellularized amniotic basement membrane grafts, including BIOVANCE and BIOVANCE 3L Ocular, for the treatment of ocular surface diseases and ophthalmic surgical applications.

- Company: DefEYE™, Inc.
- Sector: biotech
- Primary source: https://www.preqin.com/data/profile/asset/defeye--inc-/776795

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.